Company intelligence / Profile preview

ContraFect Corporation

Yonkers, New York, United Stateslinkedin.com ↗

Ownership: Public · CFRX
Development stage: Phase 3

Overview

ContraFect's lead drug candidate exebacase failed to meet primary endpoints in Phase 3 clinical trials. The company filed for Chapter 7 bankruptcy on December 4, 2023. Assets were sold to Aurobac Therapeutics SAS in March 2024.

Therapeutic areas: CardiovascularInfectious Diseases
Modalities: Direct Lytic Agents (DLAs)lysinsamurin peptidesenzymesmonoclonal antibodiesbacteriophage therapy
Industry: Biotech

Drug pipeline

5 assets

exebacase

4 more assets in the full pipeline.

Request access →

Partnerships

Collaboration with a leading hospital in Lyon, France

Financials

Market cap: $0
Total revenue: $0
Enterprise value: $-2.9M

Beyond the preview

Go deeper on ContraFect Corporation.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ContraFect Corporation.

Explore the full profile